Can be galectin-3 a novel marker in determining mortality in hemodialysis patients?(Retracted article. See vol.49,pg.942,2016)

OZKAN, Gulsum; ULUSOY, ŞÜKRÜ; MENTEŞE, AHMET; GÜVERCİN, BEYHAN; KARAHAN, SÜLEYMAN; YAVUZ, Adnan; ALTAY, Diler; OCAL, Mustafa

doi:10.1016/j.clinbiochem.2015.05.003

Can be galectin-3 a novel marker in determining mortality in hemodialysis patients?(Retracted article. See vol.49,pg.942,2016)

Atıf İçin Kopyala

OZKAN G., ULUSOY Ş., MENTEŞE A., GÜVERCİN B., KARAHAN S. C., YAVUZ A., ...Daha Fazla

CLINICAL BIOCHEMISTRY, cilt.48, sa.12, ss.768-773, 2015 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 48 Sayı: 12
Basım Tarihi: 2015
Doi Numarası: 10.1016/j.clinbiochem.2015.05.003
Dergi Adı: CLINICAL BIOCHEMISTRY
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.768-773
Karadeniz Teknik Üniversitesi Adresli: Evet

Özet

Background: Cardiovascular (CV) mortality is common in hemodialysis (HD) patients. There are some difficulties involved in determining CV risk. Galectin-3 is a molecule with a demonstrated correlation with CV mortality and which is approved in the stratification of heart failure (HF) risk. The purpose of this study was to assess the previously uninvestigated relationship between galectin-3 and cardiac mortality in HD patients.